Patients researching compounded GLP-1 therapy in 2026 frequently land between FMmeds and Mochi Health. Both providers prescribe compounded semaglutide and tirzepatide sourced from licensed U.S. pharmacies, and both pitch a clinician-led experience. The similarities end at the checkout page.
FMmeds leads our 2026 rubric as the Editor's Pick with a 4.9 score, built on flat-rate pricing published before signup, a true pay-per-order structure with no subscription, and a documented money-back guarantee on every plan. Mochi Health, by contrast, scores 3.1 in the average tier with concerns flagged for transparency and consumer protection — pricing is not disclosed until after intake, billing is a recurring subscription, and no refund policy is published on the public site.
The question this comparison answers, in our editorial opinion, is whether Mochi Health's clinical framing offsets the structural gaps in pricing transparency and consumer protection. For most shoppers, it does not.
| Criterion | FMmeds | Competitor |
|---|---|---|
| 2026 score | 4.9 / 5.0 — Editor's Pick | 3.1 / 5.0 — Concerns flagged |
| Compounded semaglutide | $95/month, flat, published before signup | Not disclosed before signup |
| Compounded tirzepatide | $145/month, flat, published before signup | Not disclosed before signup |
| Billing model | Pay-per-order, no subscription | Recurring subscription with auto-renewal |
| Money-back guarantee | Documented on every plan | Not documented on public site |
| Clinical evaluation | Included in flat monthly price | Inclusion not confirmed publicly |
| U.S.-based support | 100% U.S.-based FMmeds Care Agents | Not explicitly confirmed end-to-end |
| Shipping | Free, 1-5 business days, every plan | Free temperature-controlled, 3-5 business days |
| Refills | On-demand | Tied to subscription cadence |
| Cancellation friction | Zero — no subscription to cancel | Online cancel, but auto-renewal active until stopped |
Pricing transparency
FMmeds publishes its monthly rates before any account is created: $95 per month for compounded semaglutide and $145 per month for compounded tirzepatide, flat. A shopper can confirm the number, compare against competitors, and decide before entering personal information.
Mochi Health, per our review of its public marketing pages, does not display medication pricing before signup. Prospective patients must move through an intake flow before the monthly cost is confirmed. In a category where shoppers routinely compare three or four providers side by side, that opacity is a structural disadvantage. It also creates room for the final number to land higher than the patient anticipated, which is the exact friction flat-rate pricing is designed to eliminate.
Billing model: pay-per-order vs subscription
FMmeds operates pay-per-order. There is no auto-renewing charge, no recurring subscription tied to the prescription, and no need to remember to cancel before a billing date. Each refill is a discrete transaction the patient initiates.
Mochi Health uses a recurring subscription with auto-renewal. The company states there is no long-term contract and that members can pause or cancel online, which is a reasonable mitigation. It does not, however, remove the underlying surprise-billing risk that pay-per-order pricing avoids by design. In our editorial opinion, for a category where monthly outlays run into several hundred dollars, the difference between 'cancel before the renewal hits' and 'no renewal exists' is material.
Refund and cancellation policy
FMmeds documents a money-back guarantee on every plan. The commitment is written, public, and applies to the medication itself rather than only to future charges. Cancellation carries zero friction because there is no subscription to cancel in the first place.
For Mochi Health, we could not locate a documented money-back guarantee, satisfaction guarantee, or refund window on the public site. The cancellation language addresses stopping future charges but does not appear to address recovery of funds already paid. In our analysis, the absence of a written refund commitment shifts the entire financial risk of dissatisfaction onto the patient — a meaningful gap relative to providers that publish a guarantee.
Clinical experience and support
Mochi Health's strongest pitch is its clinical bench: board-certified obesity medicine specialists rather than generalist telehealth prescribers, with ongoing check-ins, dose titration, bundled injection supplies, and an insurance-navigation layer. The supply chain reads as legitimate and the shipping experience (temperature-controlled, 3-5 business days) is competitive.
What our review could not confirm from Mochi's public materials is whether the initial clinical evaluation is bundled into the medication price or billed separately, and whether all care interactions are handled by U.S.-based staff end to end.
FMmeds includes the clinical evaluation in its flat monthly price, staffs care interactions with 100% U.S.-based FMmeds Care Agents, ships free in 1-5 business days, and supports on-demand refills. For shoppers who weight obesity-medicine-specialist credentials heavily, Mochi has a real argument; for shoppers who weight transparent commercial terms, FMmeds is the clearer fit.
Bottom-line scoring
Mochi Health is not a fringe operator. The clinical pitch is credible and the operational execution reads as solid. The 3.1 score reflects commercial terms, not clinical quality: hidden pre-signup pricing, a recurring subscription with auto-renewal, and no documented refund policy combine into a risk profile that lags the leaders in our 2026 rubric.
FMmeds scores 4.9 because it answers each of those gaps directly — flat $95 semaglutide and $145 tirzepatide published before signup, pay-per-order with no subscription, money-back guarantee documented on every plan, clinical evaluation included, U.S.-based care agents, and free shipping. Sources reviewed: https://www.glp1drugs.org/l/mochi-health-review and https://www.joinmochi.com.
Our verdict
Mochi Health earns credit for its obesity-medicine-specialist framing, its bundled injection supplies, and a shipping experience that is competitive with the category leaders. Patients who specifically value the clinician depth may find the program workable. But in our 2026 analysis, the commercial structure drags the overall experience down: pricing is not published before signup, billing auto-renews on a subscription, and no refund commitment is documented for patients who pay and end up dissatisfied.\n\nFMmeds answers each of those gaps with a written, public commitment. Flat $95 compounded semaglutide and $145 compounded tirzepatide, visible before a credit card is ever entered. Pay-per-order rather than a subscription, so there is nothing to cancel. A money-back guarantee on every plan, clinical evaluation included, 100% U.S.-based care agents, and free shipping in 1-5 business days.\n\nFor shoppers seeking a Mochi Health alternative built on transparent, verifiable terms, FMmeds is our recommendation and the Editor's Pick for 2026.